India, April 18 -- A new UNC School of Medicine study of incretin-based medications, including newer medications such as semaglutide and tirzepatide that are widely prescribed for Type 2 diabetes and obesity, are associated with high rates of muscle loss relative to the amount of weight lost.

John A. Batsis, MD, an expert on obesity and nutrition at the UNC School of Medicine and the UNC Gillings School of Public Health, published his team's findings in Annals of Internal Medicine.

"While muscle loss is expected during weight loss, we observed that the proportion of weight loss attributable to muscle was consistently higher than anticipated across studies," said Batsis. "These findings suggest that the magnitude of muscle loss relative ...